Evaluation of erythropoietin therapy in hemodialysis patients at PKU Muhammadiyah Hospital Yogyakarta

Authors

  • Adnan Adnan Fakultas Farmasi Universitas Ahmad Dahlan
  • Haafizah Dania Fakultas Farmasi Universitas Ahmad Dahlan
  • Woro Supadmi Fakultas Farmasi Universitas Ahmad Dahlan

DOI:

https://doi.org/10.12928/pharmaciana.v8i2.7725

Keywords:

EPO, Hb, MCH, MCV, MCHC, quality of life

Abstract

Most of the patients with end-stage renal disease who undergo hemodialysis receive erythropoietin (EPO) therapy for anemia treatment. Anemia with EPO deficiency is a common complication of chronic kidney disease (CKD). EPO therapy is expected to improve anemia and quality of life of patients. This analytic observational study was conducted in a cross-sectional design. It aimed to identify the difference in red blood cell profiles, namely hemoglobin (Hb), Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), and Mean Corpuscular Hemoglobin Concentration (MCHC), and quality of life of CKD patients on EPO and non-EPO therapy at PKU Muhammadiyah Hospital in Yogyakarta. The inclusion criteria were PGK ICD N18.9 outpatients who received hemodialysis therapy at this hospital and were literate, able to understand the questionnaire, and willing to be a respondent. The results showed that there was no significant difference (p>0,05) between the red blood cells (Hb, MCV, MCH, MCHC) of the EPO and non-EPO therapy groups. The correlation between the EPO and the quality of life of patients in all of the KDQOL domains was p> 0.05. Aside from the insignificant difference between the EPO and non-EPO therapy groups, the research concluded that there was no correlation between either the EPO or the non-EPO therapy with the quality of life of hemodialysis patients.

References

Astuti, N.D., Syamsiatun, N.H., & Suryani, I., 2015, Faktor-faktor yang Berhubungan dengan Kualitas Hidup Pasien Gagal Ginjal Kronik yang Menjalani Hemodialisa di Rumah Sakit Umum Daerah Panembahan Senopati Bantul, Jurnal Nutricia,17(1): 10-16

Bhatta S, Aryal G, Kafle RK. Journal of Pathology of Nepal (2001) Vol 1, 26 – 29. Diunduh dari URL : http://nepjol.info/index.php/JPN/article/view/4446/3716

Hanif, H.M, 2009, Edial, Resiko anemia pada penyakit ginjal kronik, diunduh dari URL: http://www.jantunghipertensi.com/ginjal/112.pdf.

Hidayati, et al..2011. Evaluasi Terapi Anemia Pada Pasien ASKES dengan Gagal Ginjal Kronis yang Menjalani Hemodialisis Rutin Di RS PKU Muhammadiyah Yogyakarta.Jurnal Manajement dan Pelayanan Farmasi, Vol.No.3 / September 2011

KDIGO, 2012, Clinical Practice Guidline for Anemia in Chronic Kidney Disease, Kidney International Suplement, 2, 279-335, Boston, MA, USA.

Keown, P.A., Churchil, D.A., Poulin-costello, M., Lei, L., Gantotti, S., Agodoa, I., Gitlin, M., Gandra, S.R., Mayne, T.J., 2010, Dialysis patient treated with epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial, Hemodialysis International, 14:168-173

Mailani, F., 2015, Kualitas hidup pasien penyakit ginjal kronik yang menjalani hemodialisis: systematic review, Ners Jurnal keperawatan,11(1): 1-8

Mardyaningsih, D.P., 2014, Kualitas Hidup pada Penderita Gagal ginjal Kronik yang Menjalani terapi hemodialysis di RSUD dr. Soediran Mangun Sumarso Kabupaten Wonogiri, Skripsi, Prodi Keperawatan Stikes Kusuma Husada, Surakarta.

PERNEFRI, 2011, Konsensus Manajemen Anemia Pada Penyakit Ginjal Kronik,Perhimpunsn Nefrologi Indonesia (PERNEFRI), Jakarta.

Purwitasari, D.A., 2016, Kepatuhan Terapi Obat dan Kualitas Hidup pada Pasien Penyakit Ginjal Terminal Di RS PKU Muhammadiyah Bantul, Skripsi, Fakultas Farmasi Universitas Ahmad Dahlan, Yogyakarta.

Senduk, C.R., Palar, S., Rotty, L.W., 2016, Hubungan anemia dengan kualitas hidup pasien penyakit ginjal kronik yang sedang menjalani hemodialisis regular, Jurnal e-Clinic (eCl), 4(1): 105-110

Downloads

Published

2018-12-08

Issue

Vol. 8 No. 2 (2018): Pharmaciana

Section

Clinical and Community Pharmacy

License

Authors who publish with Pharmaciana agree to the following terms:

  1. Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.